Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q3 2021 · 10-Q
Revenue—
Net Income-$12.20M-$12.20MN/M vs Q3 2020 EPS Diluted-$0.07-$0.07N/M vs Q3 2020 Operating Income-$11,474,996N/M Operating Cash Flowderived-$20,192,317N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 13, 2021 · 44 d after period end